Following a full submission
AWMSG advice |
|
| Status: Superseded | |
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JANUARY 2023. Refer to TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only |
|
Medicine details |
|
| Medicine name | cannabidiol (Epidyolex®) |
| Formulation | 100 mg/ml oral solution |
| Reference number | 3201 |
| Indication | Adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older |
| Company | GW Research Ltd |
| BNF chapter | Central nervous system |
| Submission type | Full |
| Status | Superseded |
| Advice number | 1921 |
| NMG meeting date | 03/11/2021 |
| AWMSG meeting date | 08/12/2021 |
| Date of issue | 10/12/2021 |
| NICE guidance | TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex |
| Commercial arrangement | PAS |